Table 2 IC50 (mM) of cells after 16-h treatments of sodium alpha lipoate (LA), ascorbate (AA) and the simultaneous combination (AA&LA)
Cancer lines | Patient-derived Non-SRCC | Patient-derived SRCC | SRCC cell lines | Pancreatic | Ovarian | ||
|---|---|---|---|---|---|---|---|
Reagents | Treatment/Assessment (hr) | GPM-1 | GPM-2 | HSC-39 | KATO-3 | MIA PaCA-2 | SKOV-3 |
LA | 16/72 | 1.29 ± 0.36 | 0.69 ± 0.20 | 2.80 ± 2.20 | 1.46 ± 0.48 | 2.00 ± 0.70 | 4.13 ± 0.55 |
AA | 16/72 | 6.75 ± 3.92 | 4.79 ± 0.96 | 3.34 ± 0.97 | 3.78 ± 1.80 | 3.76 ± 1.78 | 7.67 ± 1.93 |
AA&LA | 16/72 | 4.87 ± 2.04 | 4.79 ± 2.42 | 4.29 ± 3.21 | 3.66 ± 0.70 | 3.29 ± 0.98 | 7.00 ± 2.17 |